OpenEvidence

AI-powered medical evidence search engine and clinical decision support for verified clinicians. Grounds LLM answers in licensed peer-reviewed literature (NEJM, JAMA Network) and specialty-society guidelines, with cited answers at the point of care. Expanding from text Q&A into multimodal evidence (JOMI peer-reviewed surgical video with segment-level retrieval), embedded FDA-cleared diagnostics (Pathway Labs' EchoNext ECG-based heart-disease detection), ambient documentation (Visits), autonomous research agents (DeepConsult), and enterprise EHR-embedded deployments across whole clinical workforces.

Consumer-style land grab in a B2B2C wrapper: give the product away free to individual physicians, verify identity, achieve daily-habit usage (~20M consultations/month, 1M in a single day by Mar 2026, ~45% of US doctors), then monetize the audience with ultra-high-CPM pharma advertising — the 'medical Google' playbook. Phase two, visible through 2026: convert bottom-up adoption into top-down enterprise contracts embedded in Epic (Sutter, Mount Sinai, Cedars-Sinai), distribute through Microsoft Dragon Copilot/Teams, and lock up exclusive content moats with journals and specialty societies (JAMA, NCCN algorithms, ASCO guidelines, SSO, SNO, JOMI video). Phase three now emerging: become the distribution layer for third-party clinical AI — embedding FDA-cleared diagnostics like Pathway Labs' EchoNext directly into the consultation workflow — while pitching 'medical superintelligence' agents that do hours of literature synthesis autonomously. International English-speaking markets (UK/Canada/Australia, ~15M physicians globally) and life-sciences intelligence (Veeva 'Open Vista') are next expansion vectors.

Exclusive multi-year content licenses with NEJM, JAMA Network, and a fast-growing roster of specialty societies and content types (NCCN treatment algorithms, ASCO guidelines/figures, SSO, SNO, AAFP, ACEP, and now JOMI's 357 peer-reviewed surgical videos with a segment-retrieval model) that competitors cannot legally replicate; a verified-physician user base approaching half of US doctors generating proprietary clinical-question data; and an advertising marketplace with unmatched physician reach. Distribution moat deepening via Epic-embedded enterprise rollouts, the Microsoft partnership, and its new role as the default distribution channel for third-party FDA-cleared AI (EchoNext).